Anatabine and Yerba Mate Composition for Smoking Cessation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nicotine replacement therapy has limited success in treating cigarette addiction due to the administration of a toxic and addictive substance and unpleasant taste associated with nicotine-containing products, which also fail to provide effective relief from tobacco cravings and withdrawal symptoms.
Innovation Solution
Compositions containing anatabine and Yerba maté extract in amounts found in naturally occurring foodstuffs, which are effective for temporarily reducing tobacco cravings and alleviating withdrawal symptoms without the undesirable side effects of nicotine or Yerba maté alone, formulated into various delivery forms like beverages, tablets, or lozenges.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nicotine replacement therapy is used to treat cigarette addiction, then nicotine delivery is achieved through transdermal or transmucosal devices, but the therapy involves administering a toxic and addictive substance with limited success in reducing cigarette consumption
Solution Approach 1:
The patent extracts and isolates anatabine from tobacco alkaloids, separating it from nicotine and other harmful substances. This allows the beneficial MAO inhibition effect to be retained while eliminating the toxicity and addiction associated with nicotine and other tobacco alkaloids.
Solution Approach 2:
The patent uses Yerba maté extract as an intermediary substance that modulates the effects of anatabine. The combination creates a synergistic effect where Yerba maté components enhance the craving-reducing properties of anatabine while mitigating potential side effects, providing a safer alternative to direct nicotine administration.
2Reliability
If high doses of tobacco alkaloids are administered to achieve MAO inhibition effect, then dopamine breakdown is reduced and pleasure-enhancing effects are increased, but nausea, dizziness, gastrointestinal distress, and palpitations occur
Solution Approach 1:
The patent applies local quality by selectively targeting the MAO inhibition property of anatabine while excluding other tobacco alkaloids that cause systemic side effects. The isolated anatabine provides localized therapeutic action on dopamine metabolism without the widespread toxic effects of high-dose tobacco alkaloid mixtures.
Solution Approach 2:
The patent changes the concentration parameter by using low doses of anatabine (0.05-0.5 mg) combined with Yerba maté extract, which achieves the desired MAO inhibition effect without reaching the high dose threshold that triggers adverse reactions such as nausea, dizziness, and palpitations.
3Reliability
If high doses of Yerba maté stimulants are consumed to achieve stimulatory effects, then methylxanthines are released and stimulation is increased, but palpitations, nausea, urinary dysfunction, and visual disturbances occur due to xanthine toxicity
Solution Approach 1:
The patent applies partial action by using a moderate amount of Yerba maté extract combined with anatabine, achieving sufficient stimulatory effect through the synergistic interaction between anatabine's MAO inhibition and Yerba maté's methylxanthines, without requiring excessive Yerba maté consumption that would trigger xanthine toxicity.
4Reliability
If nicotine is administered orally to provide nicotine replacement therapy, then nicotine delivery is achieved, but an unpleasant taste or burn is experienced
Solution Approach 1:
The patent creates a copy of nicotine's therapeutic effect through anatabine, which reproduces the craving-reducing and MAO inhibition properties without replicating nicotine's unpleasant taste and burn sensation. Anatabine serves as a functional analog that achieves the desired psychological effect without the sensory drawbacks.
Data Source
AI summary
Nutraceutical compositions containing anatabine and Yerba maté extract are efficacious for temporarily reducing the desire to smoke, reducing nicotine cravings, the treatment of smoking cessation, tobacco withdrawal symptoms, tobacco dependence, weight loss, and/or related disorders.